Cedars-Sinai Medical Center
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cedars-Sinai Medical Center
Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
While Forbion's new €360m venture capital fund and other investors have emerged to fund private and public companies, BARDA and other US agencies have been active supporters of biopharma firms in recent weeks. Also, KSQ grabs $80m in VC cash and VelosBios brings in $50m.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.